Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Articles

A collaboration and licensing agreement has been entered into by the Queen’s University Belfast and Ipsen.

Queen’s University Belfast Signs Collaboration and Licensing Agreement with Ipsen

Stevanato Group has extended its licensing agreement with Haselmeier for its Axis-D pen injector technology.

Stevanato Group, Haselmeier Extend Licensing Agreement for Pen Injector Technology

In their collaboration, Bristol Myers Squibb and Prellis Biologics aim to generate human antibody libraries for select targets to enable drug discovery.

Bristol Myers Squibb and Prellis Biologics Partner to Build Human Antibody Libraries

Meg Rivers is the former senior editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Podcasts

In this episode of the Drug Solutions podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview experts on up-and-coming 2022 trends in the bio/pharma industry.

Drug Solutions Podcast: 2022 Bio/pharma Trends: US-Based Suppliers, Digitization, and Sustainability

Fosun Pharma and Insilico Medicine will collaborate on AI-driven drug discovery and development of product candidates targeting multiple disease targets.

Fosun Pharma and Insilico Medicine Partner on Drug Discovery and Development Using Artificial Intelligence

The collaboration between Bristol Myers Squibb and Century Therapeutics will combine Century’s iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.

Bristol Myers Squibb and Century Therapeutics to Collaborate on Developing iPSC-derived Allogeneic Cell Therapies

The agreement expands Pfizer’s access to LNP formulation technology for mRNA vaccines and therapeutics.

Pfizer and Acuitas Therapeutics Collaborate on Lipid Nanoparticle Delivery System 

FDA has cleared an IND from Poseida Therapeutics, allowing continued development of the company’s allogeneic CAR-T cell therapy candidate for treating multiple solid tumors.

FDA Accepts IND for Poseida Therapeutics’ Allogeneic CAR-T Cell Therapy Candidate

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Particle analysis provides assurances of the quality and performance of the final dosage form in pharmaceutical development.

Without a Particle of Doubt

Feliza Mirasol is the science editor for 

Sample preparation tends to be manually labor intensive, but automating this step helps streamline the glycosylation monitoring workflow.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development